Τετάρτη 9 Οκτωβρίου 2019

The extended spectrum of RAS‐MAPK pathway mutations in colorectal cancer

The extended spectrum of RAS‐MAPK pathway mutations in colorectal cancer:

Abstract

Current clinical guidelines recommend mutation analysis for select codons in KRAS and NRAS exons 2, 3 and 4 and BRAF V600E to guide therapy selection and prognostic stratification in advanced colorectal cancer. This study evaluates the impact of extended molecular testing on the detection of RAS‐MAPK pathway mutations. Panel next‐generation sequencing results of colorectal cancer specimens from 5795 individuals from the AACR Project GENIE were included. Mutations in RAS‐MAPK pathway genes were analyzed and functionally annotated. Colorectal cancers had recurrent pathogenic pathway activating mutations in KRAS (44%), NRAS (4%), HRAS (<1%), BRAF (10%), MAP2K1 (1%), RAF1 (<1%) and PTPN11 (<1%). The proportion of colorectal cancers with pathogenic RAS pathway mutations was 37% when only KRAS codon 12 and 13 mutations were considered, 46% when also including select KRAS and NRAS exons 2, 3, and 4 mutations, 53% when including BRAF V600E mutations, and 56% when including all pathogenic mutations. Panel next‐generation sequencing testing identifies additional RAS‐MAPK pathway driver mutations beyond current guideline recommendations. These mutations have potential implications in treatment selection for patients with advanced colorectal cancer.

This article is protected by copyright. All rights reserved.

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου